FDA Science Board To Discuss Pre- And Postmarketing Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
The scientific advisory panel will discuss the agency's pre- and postmarketing safety programs for drugs and biologics at an April 15 meeting. The group will also discuss good manufacturing practices for vaccines; blood; and cell, tissue and gene products.
You may also be interested in...
FDA Drug Safety Meetings Begin In May
Advantages and disadvantages of current safety signal detection system to be discussed at May 18-19 meeting of FDA's Drug Safety & Risk Management Advisory Committee. Meeting is first in a series on drug safety issues, FDA says.
FDA Drug Safety Meetings Begin In May
Advantages and disadvantages of current safety signal detection system to be discussed at May 18-19 meeting of FDA's Drug Safety & Risk Management Advisory Committee. Meeting is first in a series on drug safety issues, FDA says.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states